P&G Stannous Fluoride Data Support "Restricted" Plaque Claim - FDA Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Data on stannous fluoride-containing dentrifices support the use of "restricted" antiplaque claims on product labeling, FDA's Nonprescription Drugs Advisory Committee Dental Plaque Subcommittee recommended during its meeting in Silver Spring, Md. Oct. 22. The panel voted 5-0 in favor of recommending the claim to FDA.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning